Decision: Favourable

Decisions Table

Study Title:

A Randomized, Double-Blind, Placebo-Controlled, Dose-Ranging Study to Evaluate the Efficacy and Safety of SPR001 (Tildacerfont) in Adult Subjects with Classic Congenital Adrenal Hyperplasia

  • NREC Code:

    22-NREC-CT-150

  • Decision:

    Favourable

  • Meeting Date:

    21/09/2022

  • Study Type:

    NREC CT

  • Principal Investigator:

    Prof Michael W. O'Reilly

  • PI Institution:

    Royal College of Surgeons in Ireland (RCSI) Smurfit Building Beaumont Hospital

  • Sponsor:

    Spruce Biosciences, Inc

Scroll to Top